- Home
- BIIB vs ANSS Comparison
BIIB vs ANSS Comparison
Compare BIIB & ANSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ANSS
- Stock Information
- Founded
- BIIB 1978
- ANSS 1970
- Country
- BIIB United States
- ANSS United States
- Employees
- BIIB N/A
- ANSS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ANSS Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- ANSS Technology
- Exchange
- BIIB Nasdaq
- ANSS Nasdaq
- Market Cap
- BIIB 25.1B
- ANSS 27.8B
- IPO Year
- BIIB 1991
- ANSS 1996
- Fundamental
- Price
- BIIB $149.78
- ANSS $340.64
- Analyst Decision
- BIIB Buy
- ANSS Hold
- Analyst Count
- BIIB 26
- ANSS 6
- Target Price
- BIIB $248.00
- ANSS $342.50
- AVG Volume (30 Days)
- BIIB 1.6M
- ANSS 532.3K
- Earning Date
- BIIB 02-11-2025
- ANSS 02-19-2025
- Dividend Yield
- BIIB N/A
- ANSS N/A
- EPS Growth
- BIIB 10.05
- ANSS 17.14
- EPS
- BIIB 11.06
- ANSS 6.48
- Revenue
- BIIB $9,607,500,000.00
- ANSS $2,467,743,000.00
- Revenue This Year
- BIIB N/A
- ANSS $13.17
- Revenue Next Year
- BIIB N/A
- ANSS $9.54
- P/E Ratio
- BIIB $13.47
- ANSS $52.90
- Revenue Growth
- BIIB N/A
- ANSS 14.30
- 52 Week Low
- BIIB $145.07
- ANSS $289.82
- 52 Week High
- BIIB $268.30
- ANSS $364.31
- Technical
- Relative Strength Index (RSI)
- BIIB 31.81
- ANSS 49.54
- Support Level
- BIIB $145.07
- ANSS $331.47
- Resistance Level
- BIIB $149.92
- ANSS $342.84
- Average True Range (ATR)
- BIIB 3.57
- ANSS 5.57
- MACD
- BIIB 0.18
- ANSS -0.82
- Stochastic Oscillator
- BIIB 22.27
- ANSS 52.10
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ANSS ANSYS Inc.
Ansys is an engineering software company that provides simulation capabilities for structural, fluids, semiconductor power, embedded software, optical, and electromagnetic properties. Ansys employs over 4,000 people and serves over 50,000 customers globally, including those in aerospace defense and automotive.